ASH 2020 | GMMG-Birma: BRAF and MEK inhibition in mutant BRAF V600E myeloma
Marc Raab, MD, German Cancer Research Center, Heidelberg, Germany, discusses the findings of the Phase II trial GMMG-Birma (NCT02834364) investigating combined BRAF and MEK inhibition in relapsed/refractory multiple myeloma patients with BRAF V600E mutations. Based on case study findings of the efficacy of downstream MAPK pathway inhibition, 12 patients were treated with the BFAF inhibitor encorafenib plus the MEK inhibitor binimetinib, a known successful combination therapy in melanoma. An overall response rate (ORR) of 83% was achieved, including a 27% near complete response (CR) rate. Early duration of response results are promising. Results demonstrate that the treatment combination is safe and can elicit rapid, deep responses in multiple myeloma patients. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Prof. Marc Raab, MD, has received research funding from Amgen, Sanofi, Heidelberg Pharma and Celgene; and has been a member of a board of directors or advisory committee for Amgen, Sanofi, Heidelberg Pharma, Novaritis, Celgene, Janssen, Bristol-Myers Squibb and Takeda.
